Tadalafil and patients preference in the treatment of erectile dysfunction / 中华男科学杂志
National Journal of Andrology
;
(12): 1145-1148, 2006.
Article
in Chinese
| WPRIM
| ID: wpr-289060
ABSTRACT
ED treatment has changed fundamentally since phosphodiesterase type 5 inhibitor (PDE5-I) came into clinical use. There are three kinds of PDE5-I available at present, Sildenafil, Vardenafil and Tadalafil. Tadalafil distinguishes from the other two by its uniquely long half-life, which lasts 17.5h, which a pharmacodynamic duration of 36h and not influenced by food and alcohol. Thus it may enable ED patients to accomplish a spontaneous intercourse without the need of prior preparation without, which can boost their confidence and self-esteem and, the most important, improve the relationship with their partner. To know patient preference counts quite a lot in optimizing the medication ED treatment.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Phosphodiesterase Inhibitors
/
Psychology
/
Psychotherapy
/
Carbolines
/
Patient Satisfaction
/
Therapeutic Uses
/
Drug Therapy
/
Tadalafil
/
Erectile Dysfunction
Limits:
Humans
/
Male
Language:
Chinese
Journal:
National Journal of Andrology
Year:
2006
Type:
Article
Similar
MEDLINE
...
LILACS
LIS